MedPath

Reducing Treatment Risk in Older Adults With Diabetes

Not Applicable
Completed
Conditions
Hypoglycemia
Primary Health Care
Type 2 Diabetes Treated With Insulin
Polypharmacy
Interventions
Behavioral: Conversation Aid
Other: Attention Control Educational Handout
Registration Number
NCT04585191
Lead Sponsor
Kaiser Permanente
Brief Summary

This study will evaluate the impact of academic detailing (evidence-based provider education) with or without patient pre-visit preparation (elicitation of values and preferences) on safe insulin de-prescribing among older patients with type 2 diabetes at risk for hypoglycemia. The hypothesis is that patients who are well-prepared for their primary care visit will engage in more informed discussions with their providers regarding re-evaluation of current treatment regimens. In clinically appropriate cases, these more effective discussions will result in safe de-prescribing and fewer future episodes of hypoglycemia.

Detailed Description

In this comparative effectiveness clinical trial, primary care physicians (PCPs) will receive 2 academic detailing sessions 6 months apart. Eligible patients (age 75 years or greater, type 2 diabetes, prescribed insulin or sulfonylureas \[SUs\], and last measured HbA1c \<=8%) of these PCPs will be randomized to receive either a pre-visit conversation aid/communication tool that elicits values and preferences regarding safe insulin/SU deprescribing \[Intervention\] or a general health education handout ("Embracing Life as You Age") \[Attention Control\]. Patient-reported outcomes (e.g., self-reported hypoglycemia episodes) and clinical outcomes (e.g., changes in glycemic regimen) will be compared between study arms. If successful, this study will provide evidence to support strategies for safer treatment in older adults with type 2 diabetes.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
450
Inclusion Criteria
  • age ≥ 75 years
  • type 2 diabetes with last measured Hemoglobin A1c (HbA1c) ≤ 8.0%
  • currently prescribed insulin and/or sulfonylureas (SUs)
  • Kaiser Permanente Northern California member
Exclusion Criteria
  • Given the requirements of this funding mechanism, we will not be able to develop new patient materials in languages other than English, and patients unable to communicate in English will be excluded.
  • Similarly, patients unable to provide informed consent and/or participate in informed decision making due to cognitive or communication-related deficits will be excluded.
  • Excluded by their primary care provider

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pre-Visit Conversation AidConversation AidPatients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled "Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me?" prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps.
General Health Education HandoutAttention Control Educational HandoutPatients in the attention control arm will receive an existing 1-page health education handout entitled "Embracing Life as You Age" which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well.
Primary Outcome Measures
NameTimeMethod
Clinical Outcome: Number of Participants With Glycemic Regimen De-prescribing6 months after initial primary care visit

Aggregate binary measure of diabetes medication deprescribing between baseline and 6-month follow-up. Greater de-prescribing is better.

De-prescribing defined as any combination of:

1. Discontinuation of either insulin or a sulfonylureas (SU)

2. Reduction in dose of insulin or SU,

3. Switch from a higher risk to lower risk version of insulin (e.g. from sliding scale insulin or basal-bolus insulin to twice daily basal insulin) and/or higher risk to lower risk oral medicine (e.g. switching from SU to other oral medicine less associated with hypoglycemia).

Patient-Reported Outcome: Number of Participants With Self-Reported HypoglycemiaPreceding 6 month period (asked 6 months after initial primary care visit)

Patient report of any low blood sugar episode in past 6 months that resulted in passing out or needing help from someone else

Secondary Outcome Measures
NameTimeMethod
Diabetes Treatment Satisfaction Questionnaire ScoresAsked 6 months after initial primary care visit

Patient-Centered Outcome: Number of Participants with improved scores on Diabetes Treatment Satisfaction Questionnaire \[8 items, scores 0 - 36, higher score is better\]

Number of Participants With Hypoglycemic-related Hospitalizations6 months following the first study-related visit

Hypoglycemic-related hospitalizations in the 6 months following the first study-related visit.

RAND Patient Satisfaction Questionnaire6 months following the first study-related visit

Patient-Centered Outcome: Number of Participants with improved scores on the RAND Patient Satisfaction Questionnaire \[5 item, score 5- 25, higher is worse\]

Perceived Efficacy in Patient - Physician Interactions6 months following the first study-related visit

Patient-Centered Outcome: Number of Participants with improved scores on Perceived Efficacy in Patient - Physician Interactions (5 - Item Survey, score 5-25, higher is better)

Trial Locations

Locations (4)

Kaiser Permanente South San Francisco

🇺🇸

San Francisco, California, United States

Kaiser Permanente Northern California

🇺🇸

San Leandro, California, United States

Kaiser Permanente Union City

🇺🇸

Union City, California, United States

Kaiser Permanente Vallejo

🇺🇸

Vallejo, California, United States

Kaiser Permanente South San Francisco
🇺🇸San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath